HAYWARD, Calif.--(BUSINESS WIRE)--Mawi DNA Technologies, a biotechnology company focusing on the
development of innovative technologies for biosampling, announces that
the U.S. Patent and Trademark Office has issued US Patent No. 9,138,205
for a Sample Recovery and Collection Device. The issuance of this patent
is a first step towards providing efficient and simple to use biosample
collection technologies.

“Our corporate mission is to improve human and animal health assessment
and research by enabling efficient, cost effective collection,
preservation and transportation of biological samples,” said Dr. Bassam
El-Fahmawi, President and CTO of Mawi DNA Technologies.

The patent covers the elements used in Mawi’s iSWAB™ technology, an
integrated system that combines a unique biosample collection and
concentration device with a variety of proprietary buffer formulations.
The iSWAB enables room temperature stabilization of DNA, RNA, proteins
and oral samples for drug screening. Mawi DNA Technologies’ product
development pipeline includes iSWAB-Blood designed to overcome current
challenges in Dry Blood Spot collection, as well as a potentially
disruptive new formula for stabilizing live, intact cells at ambient
conditions for extended time periods.

About Mawi DNA Technologies

Mawi DNA Technologies was founded in 2013 and has developed and
commercialized the iSWAB technology, an innovative system for collection
of biosamples. The company’s flagship product iSWAB-DNA has gained
significant market traction due to its ability to be used for animals
and all human population segments from infants to the elderly, robust
DNA yield and low bacterial DNA content. Mawi DNA Technologies has
established relationships with children’s hospitals for neonatal
screening and has set up an extensive network of international
distributors to market and sell iSWAB products globally. For more
information, please visit http://www.mawidna.com.